Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 16/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364465 | 1.00 | SLC22A6 (0.43) | SLC22A6DPP4CYP3A4DPP7DPP8 | |
| SCHEMBL726821 | 1.00 | SLC22A6 (0.43) | SLC22A6DPP4CYP3A4DPP7DPP8 | |
| SCHEMBL9987028 | 0.84 | DPP4 (0.44) | DPP4CYP3A4DPP7DPP8 | |
| SCHEMBL28183895 | 0.84 | DPP4 (0.49) | DPP4CYP3A4DPP7DPP8DPP9 | |
| SCHEMBL9987022 | 0.84 | DPP4 (0.44) | DPP4CYP3A4DPP7DPP8 | |
| SCHEMBL6692860 | 0.81 | DPP4 (0.43) | SLC22A6DPP4DPP7DPP8DPP9 | |
| SCHEMBL29441821 | 0.80 | DPP4 (0.55) | DPP4CYP3A4DPP7DPP8DPP9 | |
| SCHEMBL3799940 | 0.80 | DPP4 (0.41) | DPP4CYP3A4DPP7DPP8DPP9 | |
| SCHEMBL3799935 | 0.80 | DPP4 (0.41) | DPP4CYP3A4DPP7DPP8DPP9 | |
| SCHEMBL10056668 | 0.80 | CPA1 (0.49) | DPP4CYP3A4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115583935-A | Preparation method of 4- (2, 4, 5-trifluorophenyl) -3-oxybutyrate ester | 浙江工业大学 | 2023-01-10 | — | — | CN | claimed |
| EP-2609099-A2 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | USV Limited (IN) | 2013-07-03 | — | — | EP | claimed |
| US-20130158265-A1 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | USV LIMITED (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012025944-A2 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | USV LIMITED (IN) | 2012-03-01 | — | — | WO | claimed |
| WO-2011040717-A2 | METHOD FOR PREPARING INTERMEDIATE OF SITAGLIPTIN USING CHIRAL OXIRANE | HANMI HOLDINGS CO., LTD. (KR) | 2011-04-07 | — | — | WO | claimed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | claimed |
| CN-118063351-B | Green synthesis of chiral beta amino acids using biological enzymes and immobilized aminotransferase used | 北京元延医药科技股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118063351-A | Green synthesis of chiral beta amino acids using biological enzymes and immobilized aminotransferase used | 北京元延医药科技股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117467733-B | High chiral purity sitagliptin and method for preparing same by using immobilized transaminase | 北京元延医药科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117467733-A | High chiral purity sitagliptin and method for preparing same by using immobilized transaminase | 北京元延医药科技股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-115583935-A | Preparation method of 4- (2, 4, 5-trifluorophenyl) -3-oxybutyrate ester | 浙江工业大学 | 2023-01-10 | — | — | CN | disclosed |
| CN-115583935-A | Preparation method of 4- (2, 4, 5-trifluorophenyl) -3-oxybutyrate ester | 浙江工业大学 | 2023-01-10 | — | — | CN | disclosed |
| CN-103709170-A | Medicinal crude drug for reducing blood sugar | LI YOUXIANG | 2014-04-09 | — | — | CN | disclosed |
| WO-2011040717-A2 | METHOD FOR PREPARING INTERMEDIATE OF SITAGLIPTIN USING CHIRAL OXIRANE | HANMI HOLDINGS CO., LTD. (KR) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
| WO-2009045507-A3 | PROCESSES FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC REDUCTION | TEVA PHARMA (IL) | 2009-06-04 | — | — | WO | disclosed |
| US-20090123983-A1 | Processes for preparing an intermediate of sitagliptin via enzymatic reduction | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-14 | — | — | US | disclosed |
| US-20090123983-A1 | Processes for preparing an intermediate of sitagliptin via enzymatic reduction | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-14 | — | — | US | disclosed |
| WO-2009045507-A2 | PROCESSES FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045507-A2 | PROCESSES FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158265-A1 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | DPP4, DPP3, DPP9 | SLC22A6 677/4885DPP4 1/4885CYP3A4 20/4885 |
| US-20090123983-A1 | Processes for preparing an intermediate of sitagliptin via enzymatic reduction | DPP4, DPP3, SI | SLC22A6 3975/4885DPP4 1/4885CYP3A4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.